Intellectual Property Issues in Life Sciences: Disputes and Controversies highlights emerging legal, social, and regulatory issues pertaining to various areas of life sciences. Patents occupy a prominent position in the innovation systems in the life sciences, but to what extent they support, or hinder innovation is widely disputed. Life science is a broad subject including agriculture, ecology, microbiology, plant and animal sciences, health and diseases, biotechnology, etc. However, despite the broad applications of biotechnology and molecular biology techniques, profits on investments are surprisingly low. Thus, it is vitally important for universities, public research organizations, and private enterprises to protect their innovations. There are vast differences of opinion on patentability of living organisms, which are largely barred from patent protection. However, mind-sets are rapidly shifting and IP issues in life sciences are receiving increasing attention. To compete with progressive bio-based economies the developing countries are amending their IP laws to encourage investment. An effort has been made to avoid considering policy in isolation, but rather to emphasize the interplay between the policy mix, the wider institutional setting, market forces, and system organization solutions. Both empirical and conceptual chapters are included to bring them together and to yield facts and interpretations for the readers. This book presents expert opinions by frontier academicians, researchers, and attorneys on the recent challenges in the rapidly evolving life science industry. The present book offers comprehensive knowledge on the contemporary issues in life sciences to a wide range of audiences including students, scholars, researchers, legal practitioners, policymakers, and others interested in emerging intellectual property issues. Features The only compilation available on the contemporary intellectual property issues in life sciences in the post-COVID era. Focuses on the commercial, regulatory, bioethical, and socio-legal implications of patents in life sciences. Describes an integrated approach for sustained innovations in various areas of life sciences. Discusses the recent IP controversies in a pan-global context. Presents viewpoints to front-line practitioners, viz attorneys, researchers, etc.

This book is a highly readable and entertaining account of the co-evolution of the patent system and the life science industries since the mid-19th century. The pharmaceutical industries have their origins in advances in synthetic chemistry and in natural products research. Both approaches to drug discovery and business have shaped patent law, as have the lobbying activities of the firms involved and their supporters in the legal profession. In turn, patent law has impacted on the life science industries. Compared to the first edition, which told this story for the first time, the present edition focuses more on specific businesses, products and technologies, including Bayer, Pfizer, GlaxoSmithKline, aspirin, penicillin, monoclonal antibodies and polymerase chain reaction. Another difference is that this second edition also looks into the future, addressing new areas such as systems biology, stem cell research, and synthetic biology, which promises to enable scientists to ?invent? life forms from scratch.Contents: Seven Tales of a Patent; Patents and the Life Science Industries in the Modern Economy; Past: Dyes, Drugs and Domagk; Adrenaline Rushes ? Isolate, Purify ? and Patent; Science and Drug Discovery ? Ignorance, Serendipity and Rational Drug Design; Aspirin; Insulin; Penicillin and the Antibiotics; Cortisone and the Steroids; Polymerase Chain Reaction; The Gene Patent Wars; Innovations without Patents? The Polio Vaccine and Monoclonal Antibodies; Present: Big Pharma, Small Biotech; Crises, Backlashes and Counter-backlashes; Would We Have Got Where We are Today without Patents?; Future: Systems Biology, Stem Cells, ?Synbio? and the Future of Patents.

Intellectual property (IP) is a key component of the life sciences, one of the most dynamic and innovative fields of technology today. At the same time, the relationship between IP and the life sciences raises new public policy dilemmas. The Research Handbook on Intellectual Property and the Life Sciences comprises contributions by leading experts from academia and industry to provide in-depth analyses of key topics including pharmaceuticals, diagnostics and genes, plant innovations, stem cells, the role of competition law and access to medicines. The Research Handbook focuses on the relationship between IP and the life sciences in Europe and the United States, complemented by country-specific case studies on Australia, Brazil, China, India, Japan, Kenya, South Africa and Thailand to provide a truly international perspective.

This book integrates a science and business approach to provide an introduction and an insider view of intellectual property issues within the biotech industry, with case studies and examples from developing economy markets. Broad in scope, this book covers key principles in pharmaceutical, industrial, and agricultural biotechnology within four parts. Part 1 details the principles of intellectual property and biotechnology. Part 2 covers plant biotechnology, including biotic and abiotic stress tolerance, GM foods in sustainable agriculture, microbial biodiversity and bioprospecting for improving crop health and productivity, and production and regulatory requirements of biopesticides and biofertilizers. The third part describes recent advances in industrial biotechnology, such as DNA patenting, and commercial viability of the CRISPR/Cas9 system in genome editing. The final part describes intellectual property issues in drug discovery and development of personalized medicine, and vaccines in biodefence. This book is an ideal resource for all postgraduates and researchers working in any branch of biotechnology that requires an overview of the recent developments of intellectual property frameworks in the biotech sector.

A white paper for a decentralized blockchain platform to crowdfund life sciences research & tokenize biotech intellectual property rights. v1.8 is an archived white paper, originally published in mid-2017. ABSTRACT AQUA.Foundation is reimagining intellectual property (IP) rights on the blockchain frontier, starting with life science R&D. We all understand how delays in bringing new drugs and therapies to market are costing patients’ lives, in addition to tremendous amounts of wasted research dollars. AQUA unlocks collaboration, and generates new intellectual wealth by defining, protecting and providing liquidity to IP rights. AQUA is a blockchain-powered life science R&D funding platform that accelerates breakthrough drugs and therapies to market by enabling companies to monetize their IP rights. AQUA will save millions of patients from suffering and death and billions of dollars in R&D time by providing liquidity to companies in exchange for fractional IP rights early in their lifecycle. AQUA transforms illiquid but valuable IP rights into liquid, divisible, immutable, and fractional IP rights through tradable AQUA Tokens. AQUA shortens R&D lifecycles and aligns their timelines with those of investor expectations. In this way, AQUA will unleash a Cambrian explosion in life science R&D. ABOUT AQUA Creators of the AQUA Platform have the perfect balance of Life Sciences, Entrepreneurship, Deep Technical knowledge and Crypto experience. Together, Dr. Chandra Duggirala, M.D., George Burke, and Manoj Duggirala previously founded and ran a hyper-personalized digital nutritionist/nutrition delivery startup that integrated subscribers’ digital health analytics (TryFuel.com) with DNA and other biomarkers to deliver hyper-personalized meals nationwide. They took the concept from idea through successful product development, fundraising, and market execution, building a 7-figure annual run rate (ARR) company in less than 1 year. The team envisioned the AQUA project during 2017. Together, they have developed several blockchain initiatives and proofs-of-concept that reenvision Biotech R&D, Intellectual Property rights, Insurance, Cryptoeconomics, Crowdfunding, and Digital Asset Trading/Exchange.

These essays grew out of an effort at the EMBL to promote a new form of science communication on the social, ethical, and political issues that surround rapid change in the life sciences. Published in the Journal of Molecular Biology, these eighteen essays address the main topics of the future of the biosciences, biosciences and basic values, genomics and the globalization of biology, science miscommunication, and reproductive technologies. Hot topics such as cloning, genomics, reproductive technologies, heatlh care costs are addressed. Key Features * Significant to those in the life sciences and social sciences * Features an Introduction by Halldór Stefánsson * Published in conjunction with the prestigious European Molecular Biology Laboratory (EMBL)

In the current era current era of significant innovations, science and technology are powerful tools improving human welfare through prosperity and sustainable development. The development of microbiology based industries in any given country is shaped by the characteristics of its technology—particularly its close relation to scientific knowledge, and by country-specific factors such as the level and nature of the scientific knowledge base, the institutional set-up, and the role assumed by the government, all of which influence the country's ability to exploit the new opportunities. This unique book presents an integrated approach for sustained innovation in various areas of microbiology. Focusing on the industrial and socio-legal implications of IPR in microbiological advances, it offers a comprehensive overview not only of the implications of IPR in omics-based research but also of the ethical and intellectual standards and how these can be developed for sustained innovation. The book is divided into three sections discussing current advances in microbiological innovations, recent intellectual property issues in agricultural, and pharmaceutical microbiology respectively. Integrating science and business, it offers a glimpse behind the scenes of the microbiology industry, and provides a detailed analysis of the foundations of the present day industry for students and professionals alike.

Pleads For Science To Be Studied With An Integrated Approach. Presents 75 Research Papers In Different Fields Of Science-The Aims Is To Help The Scholars To Overtake Research, Training And Consultancy In Proverty Areas Of Science And Technology And Evolve Relevant Data Bases, Methodologies And Policy Frameworks In The Science And Technology Areas.

Life Sciences is one of the most innovative and complex areas of law. It is currently undergoing a period of intense transformation, with companies facing an ever-increasing level of regulation as well as strict cost management in order to remain competitive and profitable. The latest in "A User's Guide to..." series it covers life sciences in relation to: - patents - copyright - trade marks; and - data protection The book covers UK law with references to significant EPO cases. A key part of the book is the coverage of case law. Case studies and detailed analysis of the key cases, eg the Kymab mouse case, the human genome sciences case, and the pregabalin case feature heavily helping to put this often complex area of law into context. Where appropriate and for comparison purposes, approaches of key foreign jurisdictions are summarised and for ease of use there are clearly signposted. A key text for practitioners specialising in life sciences and intellectual property in general and patents officers dealing with life sciences applications.

This WIPO overview explains in simple terms how WIPO works, and how it carries out its mission of promoting a balanced IP system.